High quality stocks work long-term and also in 2020 High quality stocks work long-term and also in 2020 High quality stocks work long-term and also in 2020

High quality stocks work long-term and also in 2020

Equities 5 minutes to read
Peter Garnry

Head of Saxo Strats

Summary:  Equities have reached high valuation levels, increasing the probability for negative real rate returns over a 10-year period. But with bond yields compressed everywhere investors are desperately looking for assets that can yield over the long run. High-quality stocks have done exactly that over almost four decades and in this equity update we pick out 25 high-quality stocks with long-term potential.

Our regular readers know that our view is fundamentally negative on equities. This is especially true of US equities, which have moved to levels against European equities that are historically out of proportion. There is an increasing risk that investors buying equities at current valuation levels could experience a negative real rate return over a 10-year period. But at the same time bond yields are falling and rates in the US are potentially going negative this year. What do you do as an investor?

Our general recommendation is for long-term investors to be half-exposed to the equity market and keep the remaining part of the portfolio in cash or short-term government bonds. A bit of gold would also be a good additional diversifier. The next question is then what equities investors should invest in while they wait for a setback. Long-term quality stocks have outperformed the general market since 1981 by a large margin, and in general Warren Buffett also changed his approach over time from deep value stocks to high-quality stocks with a understandable and predictable business moat. The biggest index provider in the world, MSCI Inc., uses three fundamental ratios as the components for selecting high-quality stocks: return on equity, debt-to-equity and earnings variability.

Source: Bloomberg

We prefer return on invested capital (ROIC) over return on equity as it better reflects the return on the total capital invested. Return on equity can be inflated by using a lot of debt; think financials in the years leading up to 2008. Debt-to-equity is not our preferred metric either as we would prefer net-debt-to-assets to avoid a metric with a potential negative denominator, which could happen due to a lot of share buybacks. One case is Rockwell Automation, where its debt-to-equity ratio is a mammoth 558% due to share buybacks. But if you look at its net-debt-to-assets then the ratio is only 20%, which is still high for a quality company but easily manageable through its cash flow generation. Earnings variability is a good measure unless a big shift in the competitive landscape happens, because then you will be behind the curve as a function of your lookback window to compute this earnings variability; it’s probably better just to analyse the industry outlook and apply that human judgement.

Our preferred method is to look at ROIC/WACC, where WACC is the weighted average cost of capital. If this spread is above one then the company is creating shareholder value. Secondly a good net-debt-to-assets position combined with a strong business moat in an industry with a positive outlook are the next variables we look at. Combining these variables without regard to valuation, we filter the US and European large cap segment top to 25 high-quality stocks that could do well even during a deep recession due to COVID-19. These 25 stocks have delivered on average 10% return this year in local currencies, thus outperforming the overall equity market. However, please be aware that this is not an indication of future performance.

Mkt. Cap. (USD, mn.)EV/EBITDAROIC/WACC (%)Net-debt-to-assets (%)YTD in %
Apple IncTechnologyCommunications Equipment1,395,00616.773.63-28.910.2
ASML Holding NVTechnologySemiconductor Mfg142,00537.881.24-6.213.7
Atlas Copco ABIndustrialsFlow Control Equipment48,44417.221.837.72.6
Biogen IncHealth CareBiotech49,1936.274.432.01.6
Coloplast A/SHealth CareHealth Care Supplies35,32937.866.144.232.6
Colruyt SAConsumer StaplesFood & Drug Stores8,1939.203.10-3.513.7
eBay IncConsumer DiscretionaryE-Commerce Discretionary31,76111.322.8230.826.2
Electronic Arts IncTechnologyApplication Software35,44518.582.47-40.614.2
Euronext NVFinancialsSecurity & Cmdty Exchanges6,50714.262.2920.516.7
F5 Networks IncTechnologyCommunications Equipment8,88015.581.57-39.34.4
Facebook IncCommunicationsInternet Media660,73618.102.14-33.013.0
GlaxoSmithKline PLCHealth CareLarge Pharma104,37112.272.7932.3-4.5
Knorr-Bremse AGIndustrialsRailroad Rolling Stock17,28912.733.128.65.6
Kone OyjIndustrialsComml & Res Bldg Equip & Sys35,92622.634.86-19.87.4
Lockheed Martin CorpIndustrialsDefense Primes109,07812.263.3025.81.2
Microsoft CorpTechnologyInfrastructure Software1,386,48020.172.62-16.516.6
Monster Beverage CorpConsumer StaplesBeverages38,22324.423.20-25.314.2
Neste OyjEnergyRefining & Marketing30,78710.662.67-2.016.7
NIKE IncConsumer DiscretionaryApparel, Footwear & Acc Design154,78825.053.59-5.0-1.2
Novo Nordisk A/SHealth CareLarge Pharma151,38716.678.70-8.812.7
Novozymes A/SMaterialsSpecialty Chemicals15,35519.662.6419.811.9
Roche Holding AGHealth CareLarge Pharma299,34013.693.674.59.1
Rockwell Automation IncIndustrialsMeasurement Instruments24,86416.162.7419.67.0
Unilever PLCConsumer StaplesHousehold Products139,52413.822.8035.20.7
Visa IncFinancialsConsumer Finance377,71923.682.883.43.8

Source: Bloomberg and Saxo Group

* YTD in % is the total return year-to-date in local currency


The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)

Saxo Markets
40 Bank Street, 26th floor
E14 5DA
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo Markets is a registered Trading Name of Saxo Capital Markets UK Ltd (‘SCML’). SCML is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo Markets assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992